Description

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research[1].–80°C, protect from light-Applications-Cancer-Kinase/protease-Formula-N/A-Citation–References-[1]Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. -CASNumber-1714088-51-3-MolecularWeight-145000 (average)-Compound Purity-99.81-SMILES-[Telisotuzumab vedotin]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);c-Met/HGFR-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Protein Tyrosine Kinase/RTK-MCE Product type-ADC Related